An increased global demand for aesthetic treatments in recent years has led to the development of exciting technologies and innovative treatments. Driving this demand are several factors including social media influencers, the continuation of the ‘Zoom effect’, and advances in technology, paving the way for 2024 to be another exciting year in aesthetics.
“As co-founder and co-host of the Inside Aesthetic podcast, I am continually researching the latest trends and products,” reported cosmetic doctor and facial aesthetic injector, Jake Sloane, MD (Sydney, Australia). “One of the biggest trends in Australia that we saw in 2023 was a large drop in the number of volumizing hyaluronic acid (HA) fillers being used, due to an increase in the variety of newer injectables and a maturation of aesthetic trends.”
Dr. Sloane anticipates a newer class of injectables known as polynucleotides (PNs) to stand out in upcoming year. “Rejuran® (PharmaResearch Products Co. Ltd) is the only product to be approved here so far,” he reported. “In line with this trend of moving away from high volumes of structural HA fillers, we should see more products that improve skin quality. It is speculated that Allergan’s new hybrid filler HArmonyCa™ may launch in Australia in late 2024. The combination of HA and calcium hydroxyapatite delivers immediate volumization and longer-term biostimulatory results. Other biostimulatory products that may become available include Gouri (DEXLEVO); a novel liquid polycaprolactone (PCL) and Aesthefill (Regen Biotech); a powder-made polylactic acid (PLA) product that will rival Sculptra (Galderma, Fort Worth, Texas).”
In addition, the continued rise in demand for treatments like the Botox® (Allergan Aesthetics, an Abbvie Company) ‘lip flip’ and ‘baby botox’, along with fillers and biostimulators, may indicate a cultural shift that sees injectables as alternatives to more invasive procedures, paving the way for continued innovations in this field. Dr. Sloane added that providers should keep their eye on the newer class of botulinum toxins such as prabotulinumtoxinA- xvfs, daxibotulinum toxin, and Galderma’s relabotulinum toxin A. He anticipates that this further competition and choice among the existing toxin brands may lead to a price war, making 2024 an interesting time for injectors.